Parkinson Disease (PD) is a progressive neurodegenerative disorder with limited therapeutic options. In this issue of Cell, Martin et al. link PD protein leucine-rich repeat kinase 2 (LRRK2) to abnormalities of translational control, a pathogenic mechanism implicated in an increasing number of CNS neurodegenerative diseases, as well as in normal aging.
No therapies exist to halt the relentless neurodegeneration of Parkinson disease (PD), an increasingly common disorder of aging estimated to affect 7-10 million people worldwide. The initial symptoms of slowed movement, stiffness, and tremor caused by degeneration of midbrain dopaminergic neurons are treated by dopamine replacement therapy. Yet progressive neurodegeneration inevitably leads to debilitating treatment-resistant symptoms such as falls and dementia. Development of therapies requires an improved understanding of disease mechanisms at the cellular and molecular level.
A flurry of genetic discoveries beginning in 1997 has yielded increasing insight into the molecular underpinnings of PD (Cookson and Bandmann, 2010) . Among the key PD genes-including SNCA (encoding a-synuclein), PARKIN, DJ-1, PINK1, enthusiasm is particularly high for LRRK2. Dominantly-inherited LRRK2 missense mutations are the most common genetic cause of PD, accounting for up to 20% of PD in select clinical samples like Ashkenazi Jews, and LRRK2-related PD is typically indistinguishable from sporadic disease clinically and neuropathologically. Further, LRRK2 contains kinase and GTPase domains, enzymatic activities tractable to therapeutic targeting.
Despite intense interest and extensive study, the mechanisms through which LRRK2 mutations cause neurodegeneration are unclear. The best-characterized mutations fall within the kinase and GTPase domains and the most common, G2019S, alters the essential Asp-PheGly (''DFG'') kinase regulatory motif, enhancing its activity. Importantly, several studies report that suppressing kinase function blocks neurotoxicity. Putative substrates, including eukaryotic initiation factor 4E (eIF4E)-binding protein (4E-BP), endophilin A, and ezrin/radixin/ moesin, have yet to be comprehensively validated, particularly in PD patient tissues. Confusingly, LRRK2 has been localized to and proposed to affect nearly all cellular compartments. Nevertheless, an emerging area of focus is the role of LRRK2 in endolysosomal and autophagic pathways. This work is of particular interest because dysfunction of these pathways is an increasingly recognized theme of PD (and Alzheimer disease) pathogenesis encompassing the action of several PD-linked proteins (Trinh and Farrer, 2013) .
Translation control is another area where a role for LRRK2 is attracting growing interest. Eukaryotic translation consists of three steps: initiation, elongation, and termination (Sonenberg and Hinnebusch, 2009 ). Translational initiation is a particularly critical step, being rate limiting and tightly controlled by diverse signals reflecting cellular energy balance and stress. Two types of translation initiation exist: cap dependent and cap independent. The great majority translational initiation is cap dependent, controlled by initiation factors binding to the ''cap'' at the 5 0 end of mRNA. eIF4E binding is a critical step, but is blocked by 4E-BP. Phosphorylation of 4E-BP releases it from eIF4E, enabling translational initiation. Less frequently, translational initiation occurs independent of the cap, with assembly of the ribosome and initiation factors at an internal ribosomal entry site (IRES). IRES-mediated translation is believed to occur when cap-dependent translation is compromised, such as during stress and apoptosis. Studies in Drosophila suggest that PD mutant LRRK2 causes neurodegeneration by hyperphosphorylating 4E-BP, an effect that can be suppressed by 4E-BP overexpression (Imai et al., 2008) . 4E-BP phosphorylation by LRRK2 is also proposed to enhance translation by disrupting the miRNA pathway through an abnormal interaction with Argonaute (Gehrke et al., 2010) . The report by Martin et al. (2014) in this issue of Cell adds considerable support for the possibility that LRRK2 kinase function enhances translation but points to a distinct mechanism not involving 4E-BP. The authors first identified LRRK2 kinase substrates using a tandem affinity purification scheme that yielded several categories of LRRK2 interactors, including one featuring ribosomal proteins. After obtaining additional data supporting ribosomal proteins as potential substrates, they systematically purified 67 ribosomal proteins, subjecting them to LRRK2 kinase assays. Nineteen of these proteins could be phosphorylated by LRRK2, three of which were components of the 40S ribosomal small subunit and exhibited enhanced phosphorylation by G2019S-LRRK2.
After successfully mapping the phosphorylation sites for two of these proteins (s11 and s15), the authors asked whether nonphosphorylatable versions (threonine to alanine mutations) could block G2019S-LRRK2-induced neurodegeneration in cultured neurons. The mutation in s15 (T136A), but not those in s11, was protective, and expressing a ''phospho-mimetic'' T136D s15 molecule was itself toxic to neurons. Similar results were obtained in human ES-derived neurons, where knockdown of s15 provided partial but significant suppression of G2019S-LRRK2 toxicity. Critically, s15 was found to be hyperphosphorylated in postmortem brain protein lysates from PD subjects with the G2019S LRRK2 mutation. Seeking additional evidence, the authors turned to in vivo studies in Drosophila. Consistent with the previous data, they found the phosphorylation of s15 to be decreased in dLRRK null flies and increased in flies overexpressing human G2019S-LRRK2. Remarkably, yet surprising given the many other functions ascribed to LRRK2, overexpression of T136A s15 rescued essentially completely the climbing and dopamine neurodegenerative phenotypes in aged G2019S-LRRK2 transgenic flies.
These data alone would represent the best-characterized LRRK2 kinase substrate linked to neurodegeneration, but the authors pushed further, exploring the effects of s15 phosphorylation on translation. Using a bicistronic reporter system in cell culture, they observed a kinasedependent enhancement of both capdependent and cap-independent translation induced by G2019S-LRRK2. Similar to its ability to block neurodegeneration in neuronal culture and Drosophila, coexpression of T136A s15 blocked reporter activation by G2019S-LRRK2, including when tested in neuronal culture. To demonstrate definitely in vivo translational upregulation and its role in neurodegeneration, the authors showed a global increase of newly synthesized proteins in G2019S-LRRK2 Drosophila pulse fed 35 S, enrichment of mRNAs in heavy polysomes in such animals, and suppression of neurodegeneration in G2019S-LRRK2 Drosophila treated with low dose anisomycin to suppress translation.
While consistent with previous studies connecting LRRK2 kinase activity to enhanced translation, these experiments uniquely extend such observations to mammalian neurons and provide support for the s15 hyperphosphorylation mechanism in human PD brain lysates. The identification of a ribosomal protein as a direct LRRK2 target is striking, raising a range of mechanistic questions of potential therapeutic relevance, including how phospho-s15 mediates this effect (Figure 1) . Little is known about s15, and the somewhat unexpected increase in both cap-dependent and cap-independent translation make this protein particularly intriguing. Potentially relevant to this observation is a report implicating s15 in the nuclear export of preribosomal RNA (Rouquette et al., 2005) . The conclusions regarding the two modes of translation initiation rest largely on a bicistronic reporter assay. The relationship between these modes of translation is incompletely understood, as is the nature of mammalian IRES elements. It will be useful to further explore these findings using additional methods, including luciferasebased assays that provide quantitative measurements over a greater dynamic range. Such studies may also clarify the lack of effect seen for 4E-BP or Argonaute/Dicer proteins on LRRK2-enhanced translation.
Mechanistic issues aside, the consistent finding of translational activation by LRRK2 PD mutations is exciting, Martin et al. demonstrate that PD mutant forms of LRRK2 increase phosphorylation of the 40S ribosomal subunit s15, which increases global translation and neurodegeneration. PD mutant forms of LRRK2 stimulate both cap-dependent (shown here) and cap-independent (not shown) forms of translation. M 7 G = mRNA methylguanosine ''cap''. The phosphorylation of s15 may enhance translation through several mechanisms, including stimulation of the initiator methionine tRNA (Met-tRNAi) to 40S, enhanced binding of 40S to the eIF4F initiation, or enhanced scanning for the AUG. eIF4F is a complex of three proteins, eIF4G, eIF4A, and eIF4E. A key point of control of translational initiation is formation of the eif4F complex (not shown). eIF4F formation is blocked by 4E-BP binding to eIF4E, but this interaction is inhibited by 4E-BP phosphorylation. Previous work suggests that 4E-BP is a LRRK2 kinase substrate, but such an effect was not observed in Martin et al. potentially linking pathogenesis of this age-related disease to a key agingrelated pathway. Translational suppression (via mTOR inhibition and 4E-BP dephosphorylation) is a major consequence of caloric restriction or rapamycin treatment, interventions that extend lifespan in yeast, fly, worm, and mouse (Kennedy and Kaeberlein, 2009 ). Also fascinating is the potential convergence between LRRK2's roles in translation and endolysosomal function. Intriguingly, a recent pair of reports in Cell describes the dynamic localization of mTOR regulatory machinery to the lysosome (Demetriades et al., 2014; Menon et al., 2014) , an organelle strongly implicated in PD pathogenesis. Speculatively, LRRK2 PD mutations may disrupt the integration or transfer of information about cellular energy state, a critical determinant of translational control. As Martin et al. note, abnormalities of translational machinery have recently been discovered as the most common genetic cause of amyotrophic lateral sclerosis, and related defects underlie Fragile X-related disorders, where aberrant transcripts appear important in disease pathogenesis. Ultimately, one hopes that the findings of Martin et al. will lead to the identification of misregulated translational events that will be tractable therapeutic targets against the neurodegeneration of PD.
